

Introduction to QIBA Campaign 2021

Thanks to the dedication and efforts from all who participate in QIBA, we have made great progress in recent years. QIBA Profiles have been drafted and revised, tested, implemented, and publicized. The Accomplishments section below conveys summary observations and statistics from that activity.

To continue this impressive momentum, the QIBA Steering Committee developed a set of goals to assist QIBA Biomarker Committees in maintaining focus on the tasks most likely to increase the positive impact that QIBA Profiles can have on clinical research and practice. To reiterate, we believe those essential activities involve concentrating on Profile content, implementation, and communication.

The recommended goals, referred to as **QIBA Campaign 2021**, are listed below, following the Accomplishments.

We are very grateful for the QIBA community's continued commitment and diligence in reducing the variability associated with health care delivery.

QIBA Campaign 2021



All of us involved in QIBA can take great pride in the accomplishments of recent years. Here are some of the latest highlights and statistics.

Accomplishments



1. There are 22 active Biomarker Committees

- [Link to committee pages](#)
- [Link to org chart](#)

2. Participants


There are approximately **200 active participants** in QIBA committee representing numerous stakeholder groups:

a. Physicists:	73
b. Clinicians:	51
c. Equipment:	17
d. Government:	13 (FDA, NIH, NIST)
e. Societies:	10
f. Informatics:	8
g. Pharma:	7
h. Statisticians/Technologists:	4
i. Contract Research Organizations:	3

An additional 900 participants contribute to QIBA periodically, or are on email lists, at their request.


3. Profile Status

- **3** at **Stage 3**: Technically Confirmed
- **10** at **Stage 2**: Consensus
- **3** at **Stage 1**: Public Comment
- **9** In Early Development



4. Publications in 2020 (Q1-Q3)

- QIBA-Generated: **43**
- Publications citing QIBA: **62**





QIBA Campaign 2021 Goals

We have requested that each QIBA Biomarker Committee (BC) devote some of its meeting (conference call) time during 2021 to consider and discuss the following goals, to develop a strategy and/or plan to achieve or make progress toward each. Some of the goals may need to be adapted to be congruous with the BC's status.

- a. Obtain clinical-user input re: the potential clinical role (i.e., clinical relevance) of the imaging biomarker, and the appropriateness of the Profile Claim. The "clinical-user perspective" may reflect:
 - i. Clinical trial needs
 - ii. Clinical practice needs
 - iii. Payer perspective
- b. For Profiles that are:
 - i. In development, or Stage 1 or Stage 2, advance the Profile at least one Stage within the year.
 - ii. At Stage 3 (Technically Confirmed), write a concept proposal for clinical data collection that would help move the Profile to Stage 4 (Claim Confirmed).
- c. Draft at least one manuscript for a peer-reviewed publication.
- d. Write a concept proposal for a groundwork or clinical research project that could form the basis for an application to an external funding entity.

- e. Consider/discuss submitting a proposal to make a QIBA presentation at a professional meeting. Educationally oriented presentations to non-radiology organizations are particularly encouraged.
- f. Discuss committee leadership succession planning and recruiting new committee members, where relevant.

Questions or comments may be directed to: QIBA@rsna.org. Thank you!